Rakovina Therapeutics email archive

Live tomorrow: the kt-5000AI story with Kim Oishi, Dr. Mads Daugaard and Handol Kim

Nov 4, 2026 10:45 AM

AI narrows the focus for our brain-targeted cancer drug

Oct 30, 2026 11:32 AM

kt-5000AI update: what we’ve shown, and what’s next

Oct 22, 2026 4:17 PM

Rakovina secures exclusivity on kt-5000 target profile

Oct 18, 2026 4:14 PM · Resent

Rakovina secures exclusivity on kt-5000 target profile

Oct 15, 2026 10:30 AM

Rakovina partners with Celvion: what it means for our ATR program

Oct 1, 2026 4:18 PM

Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member

Sep 17, 2026 4:45 AM

Rakovina Therapeutics Announces Appointment of Professor Petra Hamerlik to its Board of Directors

Sep 10, 2026 4:30 AM

Rakovina Therapeutics Announces Q2 2026 Financial Results and Provides Corporate Update

Aug 31, 2026 7:00 PM

Rakovina Therapeutics Announces Final Closing of Upsized Non-Brokered Private Placement

Aug 31, 2026 4:42 PM